Guggenheim Rates Monte Rosa Therapeutics (GLUE) buy

Guggenheim maintains a bullish stance on Monte Rosa Therapeutics with a $35 price target, a 44.63% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 10:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Monte Rosa Therapeutics, Inc. ($GLUE) "buy" with a $35 price target on June 30, 2026.

Since the rating, $GLUE is up 0.8% after 1 week, down 6.3% after 1 month and down 59.8% to date (from the $24.20 close on Jun 30, 2026).

GLUE Monte Rosa Therapeutics, Inc.

$9.74 -36.38% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim reiterated its buy rating on Monte Rosa Therapeutics, setting a price target of $35.
Guggenheim's $35 price target implies 44.63% upside from Monte Rosa Therapeutics, Inc.'s ($GLUE) current $24.20 share price.
Shares of NasdaqGS:GLUE traded near $23.90 on Tuesday, with a market cap of about $1.88 billion.
Monte Rosa Therapeutics has seen varied institutional activity with notable increases from Price T Rowe and Versant Ventures.

Get $GLUE trade alerts by text

We text you when insiders, Congress or big funds trade $GLUE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Monte Rosa Therapeutics, Inc. alert may contain errors. Disclosures

Guggenheim reiterated its buy rating for Monte Rosa Therapeutics, Inc. (NasdaqGS:GLUE) on June 30, 2026. Analyst Michael Schmidt set a price target of $35, reflecting continued confidence in the company's prospects. Shares of Monte Rosa traded near $23.90 on the same day.

Other Institutional Activity in Monte Rosa Therapeutics

Several institutional investors have shown interest in Monte Rosa Therapeutics. Price T Rowe Associates increased its holdings by 1,601,284 shares, ending with 6,720,188 shares valued at approximately $110.5 million, a 31.3% increase. Versant Venture Management also grew its stake by 1,978,873 shares, holding 6,361,560 shares worth around $104.6 million, marking a 45.2% rise. BlackRock, Inc. added 1,456,523 shares to its portfolio, now holding 5,637,684 shares valued at about $92.7 million, a 34.8% increase.

Monte Rosa Therapeutics, Inc. Stock Up 99.5%

On Tuesday, shares of Monte Rosa Therapeutics traded near $23.90. The company has a market cap of roughly $1.88 billion. While it is not currently profitable, it has a forward P/E ratio of -12.29. The stock has a 52-week low of $4.12 and a high of $25.77, with a 50-day moving average of $18.98 and a 200-day moving average of $16.24. The company maintains a strong liquidity position with a current ratio of 9.54 and a quick ratio of 9.44, alongside a debt-to-equity ratio of 7.49.

12-month forecast

$GLUE price target

Monte Rosa Therapeutics, Inc. daily closes and this analyst's $35 target. Not advice.

Recent Earnings

Monte Rosa Therapeutics reported revenue of $42.95 million, though it experienced a revenue decline of 95%. The company's net margin stands at 0%, with a return on equity of -32.62%. The next earnings release is expected on August 6, 2026.

Insider Buying and Selling at Monte Rosa Therapeutics, Inc.

Recent insider activity includes Chief Medical Officer Filip Janku buying 30,000 shares at an average price of $7.56 on June 24, 2026. On the same day, he sold 30,000 shares at an average price of $21.42 under a Rule 10b5-1 plan. Chief Operating Officer Jennifer Champoux purchased 2,175 shares at $3.98 on June 23, 2026.

Analysts Set New Price Targets

On June 30, 2026, Guggenheim maintained its buy rating with a $35 price target. JP Morgan also maintained a buy rating with a $31 target on May 11, 2026. The consensus among six analysts is a buy rating, with a mean target price of $32.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, headquartered in Boston, Massachusetts, is a biotechnology company focused on developing small molecule precision medicines. It specializes in creating molecular glue degraders to treat various conditions, including MYC-driven tumors, autoimmune and inflammatory diseases, and multiple cancers. The company collaborates with F. Hoffmann-La Roche and Novartis and is led by CEO Dr. Markus Warmuth.

Bottom Line

Guggenheim's reiterated buy rating with a $35 target underscores confidence in Monte Rosa Therapeutics' potential. Investors track such analyst updates as they can influence stock performance. As a reminder, these analyses reflect backward-looking data and may not represent current market conditions.